Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

INFLUENCE OF CLINICAL-IMMUNOBIOLOGICAL FACTORS ON EFFICIENCY OF ANTIPSYCHOTIC THERAPY WITH OLANZAPINE IN PATIENTS WITH SCHIZOPHRENIA

O.A. Lobacheva, V.B. Nikitina, E.G. Kornetova, A.V. Semke, N.A. Bokhan
Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Russian Federation

SUMMARY
Objective The study of clinical and immunobiological factors in patients with schizophrenia with different efficacy of olanzapine treatment.

Patients and Methods. The study includes 29 inpatients with the verified diagnosis of schizophrenia (according to ICD-10) treated at the clinics of Mental Health Research Institute for exacerbation with response to therapy with olanzapine in the period of previous hospitalization. The assessment of degree of severity of symptoms and changes in the dynamics of the therapy with olanzapine is carried out by week 6 of the treatment with use of clinical scales PANSS, CGI. Laboratory methods include identification of parameters of cellular, humoral, phagocytic links of the immunity and concentration of cortisol in blood serum.

Results. The most expressed features of the immune status in the group of patients with high efficiency of the therapy in comparison with the group of patients with low efficiency of the treatment before administering the psychopharmacotherapy are higher values of the number of T-helpers/inducers (CD4+), natural cells-killers (CD16+) and cortisol level. The same patients have a high total score according to PANSS.

Conclusions. A complex of clinical-immunobiological parameters associated with the effect of the antipsychotic therapy is revealed that can be considered during differentiated administering the antipsychotic for heightening the efficiency of the conducted therapy.

References: 
  • 1. Klinicheskaya farmakologiya: uchebnik / pod red. V.G. Kukesa. − 3-e izd., pererab. i dop. – M.: GEOTAR-Media, 2006. – 944 s.
  • 2. Biologicheskie metody terapii psikhicheskikh rasstroistv. Dokazatel'naya meditsina – klinicheskoi praktike / pod red. S.N. Mosolova. – M.: Sotsial'no-politicheskaya mysl', 2012. – S. 491−623.
  • 3. Ivanova S.A., Fedorenko O.Yu., Smirnova L.P., Semke A.V. Poisk biomarkerov i razrabotka farmakogeneticheskikh podkhodov k personalizirovannoi terapii bol'nykh shizofreniei // Sibirskii vestnik psikhiatrii i narkologii. – 2013. – № 1 (76). – S. 12−17.
  • 4. Gurovich I.Ya., Uzbekov M.G. K ponimaniyu biomarkerov psikhicheskikh rasstroistv // Sotsial'naya i klinicheskaya psikhiatriya. – 2015. – № 3. – S. 80−83.
  • 5. Mazo G.E., Kibitov A.O. Geneticheskie markery riska razvitiya spektra metabolicheskikh narushenii pri primenenii antipsikhotikov vtoroi generatsii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2017. – № 4. – S. 2−10.
  • 6. Bagdy G., Juhasz G. Biomarkers for personalised treatment in psychiatric diseases // Expert Opin Med Diagn. – 2013. – Vol. 7, No 5. – P. 417−422.
  • 7. Mosolov S.N. Polveka neirolepticheskoi terapii: osnovnye itogi i novye rubezhi // Novye dostizheniya v terapii. – M., 2002. – S. 47−81.
  • 8. A. Khasan, Falkai P., Vobrok T., Liberman D., Glentoi B., Gattaz V.F., Meller Kh-Yu., Mosolov S.N. i dr. Rukovodstvo po biologicheskoi terapii shizofrenii Vsemirnoi federatsii obshchestv biologicheskoi psikhiatrii (WFSBP)*. Ch. 1. Obnovlennaya redaktsiya 2012 g. po terapii ostrogo pristupa shizofrenii i terapevticheski rezistentnykh sluchaev // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013. – № 1. – S. 3−40.
  • 9. Arana D., Rozenbaum D. Farmakoterapiya psikhicheskikh rasstroistv / pod red. S.N. Mosolova. – M.: BINOM, 2004. – 415 s.
  • 10. Karlson A., Lekrub'e I. Dofaminovaya teoriya patogeneza shizofrenii / per. s angl. pod red. S.N. Mosolova. – London: Taylor & Francis, 2004. – 167 s.
  • 11. Ryvkin P.V., Serditov O.V. i dr. Metabolicheskie pobochnye effekty sovremennoi antipsikhoticheskoi farmakoterapii // Sotsial'naya i klinicheskaya psikhiatriya. – 2008. – T. 18, № 3. – S. 75−90.
  • 12. Leucht S., Cipriani A., Spineli L. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis // Lancet. – 2013. – Vol. 382 (9896). – P. 951−962.
  • 13. Hutton P., Taylor P., Mulligan L. et al. Quetiapine immediate release v. placebo for schizophrenia: systematic review, meta-analysis and reappraisal // The British Journal of Psychiatry. – 2015. – Vol. 206, No 5. – P. 360−370.
  • 14. Kryzhanovskii G.N., Akmaev I.G., Magaeva S.V., Morozov S.G. Neiroimmunoendokrinnye vzaimodeistviya v norme i patologii. – M.: Meditsinskaya kniga, 2010. – 288 s.
  • 15. Vetlugina T.P., Nevidimova T.I., Lobacheva O.A., Nikitina V.B. Tekhnologiya immunokorrektsii pri psikhicheskikh rasstroistvakh. – Tomsk: Izd-vo Tomskogo un-ta, 2010. – 172 s.
  • 16. Avgustin B., Wraber B., Tavcar R. Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia // Croat Med J. – 2005. – Vol. 46, No 2. – P. 268−274.
  • 17. Maino K., Gruber R., Riedel M. et al. T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment // Psychiatry Res. – 2007. – Vol. 152, No 2–3. – R. 173−180.
  • 18. Idova G., Alperina E., Cheido M. Sontribution of brain dopamine, serotonin and opioid receptors in the mechanisms of neuroimmunomodulation: evidence from pharmacological analysis // International Immunopharmacology. – 2012. – Vol. 12, No 4. – P. 618−625.
  • 19. Muller N., Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission // Neurotox Res. – 2006. – Vol. 10, No 2. – P. 131–148.
  • 20. Androsova L.V., Sekirina T.P., Kushner S.G. i dr. Sistema interleikinov u bol'nykh shizofreniei // Zhurnal nevropatologii i psikhiatrii imeni C.C. Korsakova. – 2004. – T. 104, № 2. – S. 43−47.
  • 21. Crespo-Facorro V., Carrasco-Marín E., Pérez-Iglesias R. et al. Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: Effects of antipsychotic drugs // Psychiatry Res. – 2008. – Supll. 15. – Vol. 158, No 2. – P. 206−216.
  • 22. Kostyukova A.B., Mosolov S.N. Neirovospalitel'naya gipoteza shizofrenii i nekotorye novye terapevticheskie podkhody // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013. – № 4. – C. 2−8.
  • 23. Kochetkov Ya.A., Frolova O.G., Zhmurina M.V., Gorobets L.N. Izmenenie urovnya sekretsii leptina pri primenenii atipichnykh neiroleptikov // Klinicheskaya laboratornaya diagnostika. – 2005. – № 9. – C. 72−73.
  • 24. Rubtsova O.G., Kutuzova N.M., Bel'tikova K.V. Osobennosti izmeneniya urovnya kortizola pri depressivnykh rasstroistvakh // Estestvennye i tekhnicheskie nauki. – 2008. – № 4 (36). – C. 54−58.
  • 25. Nugent K.L., Chiappelli J., Sampath H. et al. Cortisol Reactivity to Stress and Its Association With White Matter Integrity in Adults With Schizophrenia // Psychosom Med. – 2015, Sep. – Vol. 77, No 7. – P. 733−742.
  • 26. Babinkostova Z., Stefanovski B., Janicevic-Ivanovska D. et al. / Pril (Makedon Akad Nauk Umet Odd Med Nauki). – 2015. – Vol. 36, No 1. – P. 175−183.
  • 27. Mondelli V., Ciufolini S., Belvederi Murri M. et al. Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis // Schizophr Bull. – 2015, Sep. – Vol. 41, No 5. – P. 1162−1170.
  • 28. Gurovich I.Ya., Lyubov E.B. Risperidon (rispolept) v povsednevnoi praktike lecheniya shizofrenii: Farmakoepidemiologicheskoe i farmakoekonomicheskoe issledovanie // Sotsial'naya i klinicheskaya psikhiatriya. – 2004. – № 3. – S. 44−53.
  • 29. Alfimov P.V., Oleneva E.V., Mosolov S.N. Prognosticheskie faktory terapevticheskoi effektivnosti klozapina pri shizofrenii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013. – № 2. − S. – 21−29.
  • 30. Mosolov S.N., Tsukarzi E.E., Kapiletti S.G. Antipsikhoticheskaya farmakoterapiya shizofrenii: ot nauchnykh dannykh k klinicheskim rekomendatsiyam // Biologicheskie metody terapii psikhicheskikh rasstroistv. Dokazatel'naya meditsina – klinicheskoi praktike / pod red. S.N. Mosolova. − M.: Sotsial'no-politicheskaya mysl', 2012. – S. 11−61.
  • 31. Klyushnik T.P., Zozulya S.A., Androsova L.V. i dr. Immunologicheskii monitoring endogennykh pristupoobraznykh psikhozov // Zhurnal nevrologii i psikhiatrii imeni C.C. Korsakova. – 2014. – № 114 (2). – C. 37−41.
  • 32. Müller N. Immunology of schizophrenia // Neuroimmunomodulation. – 2014. – Vol. 21, No 2−3. – P. 109−116.
  • 33. Vetlugina T., Lobacheva O., Sergeeva S. et al. Adjunctive use of interferon γ inducer for treatment of patients with schizophrenia // Acta Neuropsychiatrica. – 2015. – Vol. 16. – P. 1−8.
  • 34. Vetlugina T.P. Psikhoneiroimmunomodulyatsiya pri shizofrenii: vozmozhnosti prognoza techeniya i terapii shizofrenii na osnove immunologicheskikh podkhodov. V kn. Biologicheskie markery shizofrenii: poisk i klinicheskoe primenenie / pod red. N.A. Bokhana, S.A. Ivanovoi. – Novosibirsk: Izd-vo SO RAN, 2017. – 148 s.
  • 35. Brito-Melo G.E., Nicolato R., de Oliveira A.C. et al. Increase in dopaminergic, but not serotoninergic, receptors in T-cells as a marker for schizophrenia severity // J Psychiatr Res. – 2012, Jun. – Vol. 46, No 6. – P. 738−742.
  • 36. Fernandez-Egea E., Vértes P.E., Flint S.M. et al. Peripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia // PLoS One. – 2016, May 31. – Vol. 11 (5). – P. e0155631.
  • 37. Mosolov S.N. Shkaly psikhometricheskoi otsenki simptomatiki shizofrenii i kontseptsiya pozitivnykh i negativnykh rasstroistv. – M.: Novyi tsvet, 2001. – 238 c.
  • 38. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia // Schizophr Bull. – 1987. – Vol. 13, No 2. – P. 261−276.
  • 39. Guy W. ECDEU Assessment Manual for Psychopharmacology – Rev. Rockville, MD // U.S. National Institute of Health, Psycho–pharmacology Research Branch. – 1976. – P. 218−222.
  • 40. Khaitov R.M., Pinegin B.V. Otsenka immunnogo statusa cheloveka v norme i pri patologii // Immunologiya. – 2001. – № 4. – C. 4−6.
  • 41. Sizyakina A.P., Andreeva I.I. Spravochnik po klinicheskoi immunologii. – Rostov n/D: Feniks, 2005. – 448 s.
  • 42. Mosolov S.N., Kalinin V.V., Eremin A.V. Sravnitel'naya effektivnost' i perenosimost' novogo pokoleniya antipsikhoticheskikh sredstv pri lechenii obostrenii shizofrenii (meta-analiz original'nykh issledovanii olanzapina, risperidona, kvetiapina, klozapina i aloperidola) // Novye dostizheniya v terapii psikhicheskikh zabolevanii. – M., 2002. – S. 82−94.
  • 43. Hrdlicka M., Dudova I. Atypical antipsychotics in the treatment of early-onset schizophrenia // Neuropsychiatr Dis Treat. – 2015. – Vol. 11. – P. 907−913.
  • 44. Mosolov S.N. Osnovy psikhofarmakoterapii. – M.: Vostok, 1996. – 288 s.
  • 45. Shmukler A.B. Shizofreniya. – M.: GEOTAR-Media, 2017. – 176 s.